You just read:

Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal InTandem1 Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes

News provided by

Lexicon Pharmaceuticals, Inc.

11 May, 2017, 06:30 ET